2-Methoxyphenylboronic acid | CAS:5720-06-9

We serve 2-Methoxyphenylboronic acid CAS:5720-06-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
2-Methoxyphenylboronic acid

Product Name: 2-Methoxyphenylboronic acid
Other Name:
2-Methoxyphenylboronic acid
(2-methoxyphenyl)boronic acid
CAS No: 5720-06-9
MF: C7H9BO3
MW: 151.95600
Density: 1.17g/cm3
Boiling point: 319.3ºC at 760mmHg
Melting point: 105-110 °C(lit.)
Flash point: 146.9ºC
Refractive index: 1.524
UN Number: UN1992
UN Proper Shipping Name: ADR/RID: FLAMMABLE LIQUID, TOXIC, N.O.S.
Transport hazard class: 3
Packing group: II
 
Specification
Appearance: White to light yellow crystal powder
Assay: ≥98.0%
Water: ≤0.50%
 
Application
Applicationd as an OLED intermediate, organic intermediate, pharmaceutical intermediate.
 
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.



Contact us for information like 2-Methoxyphenylboronic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(2-methoxyphenyl)boronic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-Methoxyphenylboronic acid Use and application,2-Methoxyphenylboronic acid technical grade,usp/ep/jp grade.


Related News: Health officials said it remained unclear where he had developed the disease.L-Alanine manufacturer Health officials said it remained unclear where he had developed the disease.α-(CHLOROMETHYL)-2,4-DICHLOROBENZYL ALCOHOL supplier The two institutes that discovered Shuanghuanglian’s alleged ability to “inhibit” the coronavirus are both state-run bodies.2-[N-(2-hydroxyethyl)-4-(2-methoxyethylamino)-3-nitroanilino]ethanol vendor INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment.In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials.